From the Guidelines
Humalog 75/25 should be administered twice daily, usually before breakfast and dinner. This insulin formulation contains 75% insulin lispro protamine suspension (intermediate-acting) and 25% insulin lispro solution (rapid-acting), providing both immediate and extended glucose control 1. The specific dosage depends on individual factors including weight, blood glucose levels, diet, and activity level, and should be determined by a healthcare provider. Most patients start with a total daily dose of 0.2-0.6 units per kilogram of body weight, divided between morning and evening doses.
Key Considerations
- Blood glucose monitoring is essential when using Humalog 75/25 to ensure proper dosing and avoid hypoglycemia.
- The rapid component begins working within 15 minutes and peaks in 1-2 hours, while the intermediate component provides coverage for up to 24 hours, making twice-daily dosing appropriate for many patients 1.
- Adjustments to dosing should only be made under medical supervision.
Administration and Dosing
- Administration is usually before breakfast and before dinner 1.
- Providers should consider regimen flexibility when devising a plan for the initiation and adjustment of insulin therapy for patients with type 2 diabetes.
- If one regimen does not achieve HbA1c targets, another regimen should be considered, such as basal insulin plus a single injection of rapid-acting insulin or twice-daily premixed insulin 1.
From the Research
Humalog 75/25 Dosing Frequency
- The dosing frequency of Humalog 75/25 is typically twice daily, as indicated in the study by 2.
- This study compared the efficacy of basal-bolus therapy versus premixed insulin therapy, including Humalog 75/25, in patients with type 2 diabetes mellitus.
- The results showed that premixed therapy, dosed twice daily, was noninferior to basal-bolus therapy in achieving glycemic control.
Administration Schedule
- Humalog 75/25 can be administered immediately before or after meals, as stated in the study by 3.
- This flexibility in administration schedule may enable patients to achieve better glycemic control and improve patient satisfaction with treatment.
- However, the optimal dosing frequency and administration schedule may vary depending on individual patient needs and circumstances.
Comparison with Other Insulin Therapies
- Studies have compared the efficacy and safety of Humalog 75/25 with other insulin therapies, such as insulin glargine and insulin detemir, as reported in the studies by 4, 5, and 6.
- These studies have shown that Humalog 75/25 is noninferior to these other insulin therapies in achieving glycemic control, but may be associated with a higher risk of hypoglycemia.
- The choice of insulin therapy should be individualized based on patient characteristics, lifestyle, and medical history.